- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07636759
AI ECG Algorithm for Detecting LV Systolic Dysfunction
Prospective Observational Cohort Study of Deep Learning-based ECG Algorithm for Detecting Left Ventricular Systolic Dysfunction
Studieoversikt
Detaljert beskrivelse
Left ventricular systolic dysfunction (LVSD) is associated with an increased risk of heart failure, hospitalization, and mortality. Although transthoracic echocardiography is the standard method for assessing left ventricular ejection fraction (LVEF), its widespread use as a screening tool is limited by availability, cost, and the need for specialized personnel. Artificial intelligence (AI)-based electrocardiography (ECG) algorithms have emerged as promising tools for identifying patients with reduced LVEF using routinely acquired ECG signals.
DeepECG LVSD is a deep learning-based ECG algorithm developed to detect LVSD (LVEF ≤40%) from standard 12-lead ECG recordings. Previous retrospective validation studies demonstrated high diagnostic performance; however, prospective clinical validation in real-world practice remains limited.
The purpose of this prospective observational cohort study is to evaluate the diagnostic performance and clinical utility of DeepECG LVSD in adult patients undergoing both ECG and transthoracic echocardiography at Ajou University Hospital. Approximately 15,000 patients aged 19 years or older who have undergone ECG and echocardiography within 30 days will be enrolled.
The primary objective is to assess the accuracy of the AI algorithm for detecting LVSD using echocardiographic LVEF as the reference standard. Diagnostic performance will be evaluated using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy.
Secondary objectives include evaluating the association between AI-predicted LVSD and short-term clinical outcomes, including 30-day all-cause mortality, emergency department visits, and heart failure rehospitalization. Exploratory subgroup analyses will assess algorithm performance according to demographic and clinical characteristics, including age, sex, heart failure status, chronic kidney disease, hypertension, diabetes mellitus, and the interval between ECG and echocardiography.
This study is designed as a minimal-risk observational study and will provide prospective evidence regarding the effectiveness of AI-enabled ECG screening for LVSD in routine clinical practice. Findings from this study may support broader implementation of AI-based ECG tools for the early identification of patients at risk for heart failure and reduced left ventricular systolic function.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: MOONSEUNG SOH, MD
- Telefonnummer: +82-31-219-5111
- E-post: mssoh7701@gmail.com
Studiesteder
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, Sør -Korea, 16499
- Rekruttering
- Ajou University School of Medicine
-
Ta kontakt med:
- MOONSEUNG SOH, MD
- Telefonnummer: +82-31-219-5111
- E-post: mssoh7701@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Adults aged ≥19 years.
- Patients who underwent both transthoracic echocardiography and 12-lead electrocardiography (ECG) at Ajou University Hospital in the outpatient, inpatient, or emergency department setting.
- ECG and echocardiography performed within 30 days of each other.
Exclusion Criteria:
- Interval between ECG and echocardiography greater than 30 days.
- Missing or corrupted original ECG waveform data (XML or HL7 format).
- Presence of an implanted cardiac device, including a permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device.
- Missing age, sex, or left ventricular ejection fraction (LVEF) data.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Adults aged ≥19 years with ECG and echocardiography performed within 30 days
Adult patients aged 19 years or older who underwent both transthoracic echocardiography and electrocardiography (ECG) within 30 days of each other
|
There is no intervention group
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
AUROC for detection of LVSD (LVEF ≤40%)
Tidsramme: During procedure
|
Diagnostic performance including AUROC, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy.
|
During procedure
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Lopez-Jimenez F, Alger HM, Attia ZI, Barry B, Chatterjee R, Dolor R, Friedman PA, Greene SJ, Greenwood J, Gundurao V, Hackett S, Jain P, Kinaszczuk A, Mehta K, O'Grady J, Pandey A, Pullins C, Puranik AR, Ranganathan MK, Rushlow D, Stampehl M, Subramanian V, Vassor K, Zhu X, Awasthi S. A multicenter pragmatic implementation study of AI-ECG-based clinical decision support software to identify low LVEF: Clinical trial design and methods. Am Heart J Plus. 2025 Mar 21;54:100528. doi: 10.1016/j.ahjo.2025.100528. eCollection 2025 Jun.
- Choi J, Lee S, Chang M, Lee Y, Oh GC, Lee HY. Author Correction: Deep learning of ECG waveforms for diagnosis of heart failure with a reduced left ventricular ejection fraction. Sci Rep. 2022 Oct 13;12(1):17191. doi: 10.1038/s41598-022-22012-7. No abstract available.
- Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, Pellikka PA, Enriquez-Sarano M, Noseworthy PA, Munger TM, Asirvatham SJ, Scott CG, Carter RE, Friedman PA. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019 Jan;25(1):70-74. doi: 10.1038/s41591-018-0240-2. Epub 2019 Jan 7.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- AJOUIRB-OB-2026-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .